Chemistry: analytical and immunological testing – Biospecific ligand binding assay – Utilizing isolate of tissue or organ as binding agent
Reexamination Certificate
2011-07-05
2011-07-05
Gussow, Anne M. (Department: 1643)
Chemistry: analytical and immunological testing
Biospecific ligand binding assay
Utilizing isolate of tissue or organ as binding agent
C436S518000
Reexamination Certificate
active
07972870
ABSTRACT:
This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or inflammatory cell growth and/or activation. The invention provides methods of inhibiting interactions between MUC1 and a heat shock factor, method of inhibiting interactions between transcription factors and the MUC1 promoter, and methods of inhibiting MUC1 expression. The invention also provides screening methods for identifying compounds that inhibit the aforementioned interactions. Pharmaceutical compositions containing the identified compounds can be useful in treating cancers and inflammatory conditions.
REFERENCES:
patent: 4497796 (1985-02-01), Salser et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4675382 (1987-06-01), Murphy
patent: 4894227 (1990-01-01), Stevens et al.
patent: 4963484 (1990-10-01), Kufe
patent: 5053489 (1991-10-01), Kufe
patent: 5080898 (1992-01-01), Murphy
patent: 5380712 (1995-01-01), Ballance et al.
patent: 5506343 (1996-04-01), Kufe
patent: 5530101 (1996-06-01), Queen et al.
patent: 5565334 (1996-10-01), Kufe et al.
patent: 5597457 (1997-01-01), Craig et al.
patent: 5612895 (1997-03-01), Balaji et al.
patent: 5766833 (1998-06-01), Balance et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5790421 (1998-08-01), Osslund
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5827516 (1998-10-01), Urban et al.
patent: 5861381 (1999-01-01), Chambon et al.
patent: 5874415 (1999-02-01), Kufe et al.
patent: 5965386 (1999-10-01), Kerry-Williams et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6004746 (1999-12-01), Brent et al.
patent: 6020363 (2000-02-01), Hirano et al.
patent: 6054438 (2000-04-01), Taylor-Papadimitriou et al.
patent: 6074841 (2000-06-01), Gearing et al.
patent: 6093573 (2000-07-01), Beamer et al.
patent: 6222020 (2001-04-01), Taylor-Papadimitriou et al.
patent: 6303302 (2001-10-01), Rupp et al.
patent: 6344203 (2002-02-01), Sandrin
patent: 6589921 (2003-07-01), Herrmann et al.
patent: 6716627 (2004-04-01), Dobie
patent: 6716966 (2004-04-01), Madiyalakan et al.
patent: 7147850 (2006-12-01), Madiyalakan
patent: 2002/0110841 (2002-08-01), Kufe
patent: 2003/0235857 (2003-12-01), Rupp et al.
patent: 2004/0018181 (2004-01-01), Kufe et al.
patent: 2004/0166543 (2004-08-01), Kufe
patent: 2004/0209832 (2004-10-01), McSwiggen
patent: 2005/0042209 (2005-02-01), Kufe et al.
patent: 2005/0053606 (2005-03-01), Kufe et al.
patent: 2006/0019256 (2006-01-01), Clarke et al.
patent: 2007/0105767 (2007-05-01), Kharbanda et al.
patent: 2008/0090770 (2008-04-01), Belmares et al.
patent: 2008/0286264 (2008-11-01), Kufe
patent: 1103623 (1998-07-01), None
patent: WO 93/20841 (1993-10-01), None
patent: WO 96/03502 (1996-02-01), None
patent: WO 99/23114 (1999-05-01), None
patent: WO 91/09867 (1999-07-01), None
patent: WO 00/09744 (2000-02-01), None
patent: WO 00/11206 (2000-03-01), None
patent: WO 00/25827 (2000-05-01), None
patent: WO 00/34468 (2000-06-01), None
patent: WO 00/47763 (2000-08-01), None
patent: WO 00/77031 (2000-12-01), None
patent: WO 01/12217 (2001-02-01), None
patent: WO 01/18035 (2001-03-01), None
patent: WO 01/57068 (2001-08-01), None
patent: WO 02/22685 (2002-03-01), None
patent: WO 02/31512 (2002-04-01), None
patent: WO 02/058450 (2002-08-01), None
patent: WO 2003/014303 (2003-02-01), None
patent: WO 2003/088995 (2003-10-01), None
patent: WO 2004/044160 (2004-05-01), None
patent: WO 2004/092339 (2004-10-01), None
Skolnick and Fetrow. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin binding and mitogenic activities of heparin binding (acidic fibroblast) growth factor-1 from its receptor binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Ren et al., “MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling,”Mol. Cancer Res., 4(11): 873-883, 2006.
U.S. Appl. No. 10/486,278, filed Jun. 23, 2004, Reinherz et al.
U.S. Appl. No. 60/308,307, filed Jul. 27, 2001, Kufe.
U.S. Appl. No. 60/502,111, filed Sep. 11, 2003, Jecminek et al.
“MUC-1/X mucin short variant,” GenBank Accession No. AAD10856, dated Jun. 5, 2001.
“MUC-1/Z mucin short variant,” GenBank Accession No. AAD10858, dated Jun. 5, 2001.
“Mucin 1 precursor, non-repetitive splice from Y [validated]-human,” GenBank Accession No. S48146, dated Apr. 20, 2000.
Abe et al., “Characterization of cis-acting elements regulating transcription of the human DF3 breat carcinoma-associated antigen (MUC1) gene,”Proc. Natl. Acad. Sci. USA., 90:282-286, 1993.
Abe et al., “Identification of a family of high molecular weight tumor-associated glycoproteins,”J. Immun., 139:257-261, 1987.
Abe et al., “Sequence Anaylsis of the 5′ region of the human DF3 breast carcinoma-associated antigen gene,”Bio. Biophys. Research Comm., 165:644-649, 1989.
Abe et al., “Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells,”Cancer Res., 44:4574-4577, 1984.
Abe et al., “Structural analysis of the DF3 human breat carcinoma-associated protein,”Cancer Res., 49:2834-2839, 1989.
Abe et al., “Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells,”J. Cell. Physio., 143:226-231, 1990.
Adams and Cory, “The Bcl-2 Protein Family: Arbiters of Cell Survival,”Science, 281:1322-1326, 1998.
Agrawal and Kandimalla, “Antisense therapeutics: is it as simple as complementary base recognition?”Molecular Medicine Today, 6:72-81, 2000.
Akagi et al., “CA19-9 epitope a possible marker for MUC-1/Y protein,”Int. J. Oncol., 18:1085-1091, 2001.
Alfieri et al., “Activation of heat-shock transcription factor 1 by hypertonic shock in 3T3 cells,”Biochem. J., 319:601-606, 1996.
Apostolopoulos et al., “Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein,”British J. Cancer., 67:713-720, 1993.
Arklie et al., “Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers,”Int. J. Cancer, 28:23-29, 1981.
Ashkenazi and Dixit, “Apoptosis control by death and decoy receptors,”Curr. Opin. Cell Biol., 11:255-260, 1999.
Ashkenazi and Dixit, “Death Receptors: Signaling and Modulation,”Science, 281:1305-1308, 1998.
Ashkenazi et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand,”J. Clin. Invest., 104:155-162, 1999.
Backstom et al., “Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells,”Biochemical Journal, 376:677-686, 2003.
Banerjee, “Omega amino acids in peptide design: incorporation into helices ,”Biopolymers, 39:769-77, 1996.
Barrett et al., “PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen?,”Int. J. Cancer, 101:581-588, 2002.
Barry and Sharkey, “Observer reproducibility during computer-assisted planimetric measurements of nuclear features,”Hum. Pathol., 16:225-7, 1985.
Barry et al., “Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia,”Biochemical Pharmacology, 40:2353-2362, 1990.
Baruch et al., “Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function,
Dana-Farber Cancer Institute Inc.
Fulbright & Jaworski
Gussow Anne M.
LandOfFree
Methods and compositions relating to the regulation of MUC1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions relating to the regulation of MUC1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions relating to the regulation of MUC1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2631827